Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Hims & Hers Health Inc (NYSE: HIMS) closed the day trading at $11.90 down -3.57% from the previous closing price of $12.34. In other words, the price has decreased by -$3.57 from its previous closing price. On the day, 4.83 million shares were traded. HIMS stock price reached its highest trading level at $12.3 during the session, while it also had its lowest trading level at $11.81.
Ratios:
For a better understanding of HIMS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.54 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 54.26. For the most recent quarter (mrq), Quick Ratio is recorded 2.74 and its Current Ratio is at 3.00. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on April 16, 2024, Downgraded its rating to Hold and sets its target price to $15 from $17 previously.
On April 10, 2024, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $20.
Imperial Capital Upgraded its In-line to Outperform on February 28, 2024, while the target price for the stock was maintained at $16.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 15 ’24 when Boughton Soleil sold 2,503 shares for $13.95 per share. The transaction valued at 34,917 led to the insider holds 164,363 shares of the business.
Baird Melissa sold 11,751 shares of HIMS for $173,254 on Apr 08 ’24. The Chief Operating Officer now owns 538,932 shares after completing the transaction at $14.74 per share. On Apr 05 ’24, another insider, Baird Melissa, who serves as the Chief Operating Officer of the company, sold 11,751 shares for $14.58 each. As a result, the insider received 171,372 and left with 538,932 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 2549574912 and an Enterprise Value of 2338545664. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.92 while its Price-to-Book (P/B) ratio in mrq is 7.38. Its current Enterprise Value per Revenue stands at 2.682 whereas that against EBITDA is -141.79.
Stock Price History:
The Beta on a monthly basis for HIMS is 0.99, which has changed by 0.0076206923 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $17.16, while it has fallen to a 52-week low of $5.65. The 50-Day Moving Average of the stock is -10.84%, while the 200-Day Moving Average is calculated to be 31.39%.
Shares Statistics:
Over the past 3-months, HIMS traded about 5.07M shares per day on average, while over the past 10 days, HIMS traded about 4452840 shares per day. A total of 205.10M shares are outstanding, with a floating share count of 139.59M. Insiders hold about 34.85% of the company’s shares, while institutions hold 38.66% stake in the company. Shares short for HIMS as of 1711584000 were 12978725 with a Short Ratio of 2.56, compared to 1709164800 on 12650329. Therefore, it implies a Short% of Shares Outstanding of 12978725 and a Short% of Float of 8.1199996.
Earnings Estimates
The dynamic stock of Hims & Hers Health Inc (HIMS) is currently being evaluated by a team of 9 analysts, each contributing to its current rating.On average, analysts expect EPS of $0.01 for the current quarter, with a high estimate of $0.02 and a low estimate of -$0.04, while EPS last year was -$0.05. The consensus estimate for the next quarter is $0.01, with high estimates of $0.03 and low estimates of -$0.03.
Analysts are recommending an EPS of between $0.14 and -$0.11 for the fiscal current year, implying an average EPS of $0.05. EPS for the following year is $0.2, with 10 analysts recommending between $0.33 and $0.02.
Revenue Estimates
10 analysts predict $270.45M in revenue for the current quarter. It ranges from a high estimate of $271.65M to a low estimate of $268.9M. As of the current estimate, Hims & Hers Health Inc’s year-ago sales were $190.77M, an estimated increase of 41.80% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $288.11M, an increase of 40.60% less than the figure of $41.80% in the same quarter last year. There is a high estimate of $291.91M for the next quarter, whereas the lowest estimate is $284.6M.
A total of 12 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $1.2B, while the lowest revenue estimate was $1.18B, resulting in an average revenue estimate of $1.19B. In the same quarter a year ago, actual revenue was $878M, up 35.70% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $1.48B in the next fiscal year. The high estimate is $1.56B and the low estimate is $1.42B. The average revenue growth estimate for next year is up 24.50% from the average revenue estimate for this year.
